Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and High Dose Cyclophosphamide in Multiple Myeloma
NCT00258206Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2004
- Primary completion
- Sep 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in multiple myeloma (MM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Dec 2004; status: completed.
02
Drugs
rituximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00258206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258206.